開催日時 & 会場
- 2020年8月6日、 16:00-17:00
- 会場:オンライン(Zoom)
演者
Dr. Daisuke Muraoka
Department of Oncology, Graduate School of Biomedical Sciences, Nagasaki University
概要
Immune checkpoint inhibitors and gene-engineered T cell therapy are becoming very important for the treatment of advanced human cancers. However, it also has been revealed that a large part of cancer patients is still refractory to these immunotherapies. There can be multiple underlying mechanisms for tumor immune resistance. Especially the differences in tumor microenvironment (TME) has been considered key factors associated with tumor response to immune therapies. Therefore, various strategies to preferably manipulate TME have been tested in preclinical and clinical to improve the efficacy of existing immunotherapies. Here, we demonstrate that the antigen-loaded nanoparticle-mediated induction of antigen- presentation in tumor-associated macrophages or the small molecules- mediated activation of tumor-infiltrating T cells can improve the TME, leading to the reversal of tumor immune resistance.